BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Cicada Innovations Expands to Westmead Health & Innovation District with Investment NSW Support

The incubator will be the first health-focused incubator funded by the NSW government to support pre-revenue health-tech startups in bridging the gap betwe...

August 04, 2023 | News

Peter Mac launches BindiMaps to help patients and visitors with vision impairments

The newly-installed service functions like Google Maps, but has been specifically developed to work indoors with a 10 to 20 times higher accuracy than GPS ...

August 03, 2023 | News

NAVI Raises $2.4 Million for Breakthrough Medical Device Aiding Critically Ill Newborns

After a successful raise Navi Medical Technologies has closed a $2.4 million round of funding, which included a $700,000 lead in...

August 03, 2023 | News

MSD and Moderna Launch Phase 3 Study for Melanoma Treatment

“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phas...

July 28, 2023 | News

Hummingbird Bioscience Advances HMBD-001 Phase IB Trials in Australia, Partners with Omico for Faster Clinical Development

Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung ca...

July 27, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

July 25, 2023 | News

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

July 25, 2023 | News

ConcertAI's TeraRecon Expands Relationship with Change Healthcare for Advanced Visualization in Australia

Advanced visualization and AI leader TeraRecon, a ConcertAI company, is excited to announce an expansion of its reseller and service agreement in Aust...

July 24, 2023 | News

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Summary Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cash flow ($10.8M, an improvemen...

July 20, 2023 | News

Merck and Telix Continue Collaboration for Targeted Radiation Therapy Studies.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Com...

July 19, 2023 | News

Antengene Administers First Patient in US Clinical Study of ATG-017 for Advanced Solid Tumors with Nivolumab Combination

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop...

July 18, 2023 | News

Antengene's XPOVIO® Approved in Hong Kong for Relapsed Multiple Myeloma

XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...

July 17, 2023 | News

Stay Connected